MEDICINES PATENT POOL (MPP), an UN-backed non-profit, works to make medical treatment and technology globally accessible. It has signed an agreement with 130-year-old pharma giant Merck (known as MSD in India) to sub-license the formulation Molnupiravir to manufacture and market in more than 105 countries mostly in Africa and Asia. Molnupiravir was first invented at Emory University in Atlanta. It was then licensed to Ridgeback Biotherapeutics, based in Miami, Florida, which in turn collaborated with Merck for developing the drug. Molnupiravir, the oral antiviral drug is indicated in mild to moderate Covid-19 positive patients. The results of the Phase 3 trials reduced the risk of hospitalization or death by 50% compared with placebo. The regulatory authorities are expected to authorize the investigational Covid pill in November. MSD’s agreement with MPP will empower Indian companies, shown in my poster, to make and market Molnupiravir at a price less than $20 a course (two capsules a day for five days) as compared to more than $700 a course in the USA. Partnership and collaboration of all the organizations, in the poster, is a great example of global effort to fight the current pandemic.